Printer Friendly

Oxford to receive patent for proteomics platform technology.

Oxford GlycoSciences Plc (Oxford, England) has received notice from the European Patent Office that it intends to grant OGS a patent covering the fundamental platform technology it has developed for use in conducting proteomics research.

The patent gives OGS proprietary rights to computer-assisted methods and apparatus for identifying and isolating biomolecules in a biological sample. The patent is expected to be granted in Q1 2003. Corresponding patents have already been granted to OGS in the United States.

David Ebsworth, Ph.D., CEO of OGS said, "This patent is an affirmation that OGS is at the forefront of innovation and excellence in proteomics research. It also presents the opportunity for additional revenue through licensing to pharmaceutical and other companies which utilize processes we have developed in their proteomics research."

Oxford GlycoSciences is a research and product development company with three distinct business units -- proteomics, inherited storage disorders and oncology. In proteomics, the comprehensive study of proteins, Oxford GlycoSciences has developed a patented technology platform, integrating high-throughput proteomics with genomics. Oxford GlycoSciences has proteomics collaborations with Bayer, Pioneer Hi-Bred/DuPont, GlaxoSmithKline, Pfizer, the Center for Drug Evaluation and Research of the United States Food and Drug Administration (FDA), and the Cystic Fibrosis Foundation. Oxford GlycoSciences also has a joint venture, Confirmant Limited, to develop the Protein Atlas of the Human Genome. The second business unit is focused on the development of therapeutics to treat inherited glycosphingolipid (GSL) storage disorders. Its first product, Zavesca (miglustat) has been approved by the European Commission for the treatment of mild to moderate type 1 Gaucher disease in patients for whom enzyme replacement therapy is unsuitable. Zavesca is also undergoing further clinical investigations in other GSL storage disorders, including Late Onset Tay Sachs, Niemann-Pick type C and type 3 Gaucher disease. In oncology, Oxford GlycoSciences is developing a pipeline of projects and has drug discovery and development alliances with Medarex, NeoGenesis and BioInvent.

Oxford GlycoSciences Plc +1-212-850-5626 www.ogs.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Oxford GlycoSciences Plc
Publication:BIOTECH Patent News
Geographic Code:4EUUK
Date:Jan 1, 2003
Words:323
Previous Article:PharmaGap patents new method to grow skin stem cells.
Next Article:Cordis sues Boston Scientific alleging stent patent infringement.
Topics:


Related Articles
Use of modern proteomics to discover protein biomarkers of disease.
Oxford GlycoSciences and Cellular Genomics establish joint proteome program.
Oxford files patent application with Pfizer on Alzheimer's Disease markers.
Oxford GlycoSciences files patent application for breast cancer proteins and genes.
Executive Briefing.
Oxford Glycosciences and Cambridge Antibody Technology announce strategic alliance in protein microarrays.
Medarex and Oxford Glycosciences form alliance to develop human therapeutic antibody products.
Oxford announces grant of expanded high-throughput proteomics patent.
GeneProt licences Oxford's automated proteomics patents.
Cambridge Antibody to merge with Oxford Glycosciences.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters